Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a note issued to investors on Monday. They presently have a $242.00 price target on the biopharmaceutical company’s stock. BTIG Research’s price target points to a potential upside of 47.80% from the company’s current price.
SHPG has been the topic of several other research reports. BidaskClub lowered shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Friday, June 16th. HSBC Holdings plc lowered shares of Shire PLC from a “hold” rating to a “reduce” rating in a research note on Friday, May 19th. Royal Bank Of Canada restated an “outperform” rating and issued a $221.00 price target on shares of Shire PLC in a research note on Tuesday, April 18th. Sanford C. Bernstein lowered shares of Shire PLC from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $209.22 to $161.09 in a research note on Thursday, May 25th. Finally, Goldman Sachs Group, Inc. (The) restated a “focus list” rating on shares of Shire PLC in a research note on Tuesday, March 21st. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $227.45.
Shares of Shire PLC (NASDAQ SHPG) traded up 0.31% during trading on Monday, reaching $163.74. The company had a trading volume of 1,497,731 shares. Shire PLC has a 52-week low of $158.88 and a 52-week high of $209.22.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.22 by $0.41. The firm had revenue of $3.57 billion for the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. Shire PLC’s revenue was up 109.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.12 EPS. Equities research analysts forecast that Shire PLC will post $14.88 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Shire PLC’s (SHPG) Buy Rating Reiterated at BTIG Research” was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2723905/shire-plcs-shpg-buy-rating-reiterated-at-btig-research.html.
A number of hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new stake in shares of Shire PLC during the fourth quarter worth $505,000. Vident Investment Advisory LLC acquired a new stake in shares of Shire PLC during the fourth quarter worth $340,000. Teachers Advisors LLC boosted its stake in shares of Shire PLC by 24.6% in the fourth quarter. Teachers Advisors LLC now owns 250,804 shares of the biopharmaceutical company’s stock worth $42,732,000 after buying an additional 49,443 shares during the last quarter. Macquarie Group Ltd. boosted its stake in shares of Shire PLC by 2.2% in the fourth quarter. Macquarie Group Ltd. now owns 1,417 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 31 shares during the last quarter. Finally, Hills Bank & Trust Co. boosted its stake in shares of Shire PLC by 10.0% in the first quarter. Hills Bank & Trust Co. now owns 3,405 shares of the biopharmaceutical company’s stock worth $593,000 after buying an additional 310 shares during the last quarter. Hedge funds and other institutional investors own 21.06% of the company’s stock.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.